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Summary
C5 plays a major role in complement activation; C5 convertase cleaves C5
into the pro-inflammatory C5a, and C5b, the nidus for the formation of
the lytic membrane attack complex. C5 is a major target for anti-comple-
ment drugs, necessitating better methods for the study of C5 function.
Purification of C5 is complicated; classical methods involve precipitation
or pH shifts that result in functional loss and low yield. We here present
a method for C5 purification using a novel anti-C5 monoclonal antibody
(mAb); RO7112689 (C5i mAb, SKY59), pH-switch engineered to induce
antibody–antigen dissociation in the acidic endosome (~ pH 55).
RO7112689 was bound on an affinity column; applied serum was com-
pletely depleted of C5. Elution at pH 5 produced fully active C5 at 98%
yield. The mAb also bound C5b in the C5b6 complex, preventing C5b6
binding to target membranes and enabling purification of C5b6 from acti-
vated serum. RO7112689 inhibited C5 in mouse serum and efficiently
purified mouse C5. Used as capture, RO7112689 produced sensitive and
specific assays for human and mouse C5. This novel antibody enables effi-
cient production of intact, fully active, pure human and mouse C5, and
quantification of C5 in these species. The demonstration that RO7112689
binds C5b6 adds an additional mechanism of membrane attack complex
inhibition by this mAb.
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Introduction
The complement system, a network of over 30 fluid-
phase and cell-membrane-bound proteins and regula-
tors, is a critical component of the innate immune
defence against infection.1 Recent studies have broad-
ened our view of complement – a mediator of pleiotro-
pic effects including inflammation, modulation of
adaptive immunity, metabolism and neuronal develop-
ment.2–4 Complement activation pathways all lead to
the formation of a C3-cleaving enzyme (C3 convertase;
C4b2a or C3bBb) that yields C3a and C3b; addition of
C3b to the C3 convertase generates a C5 convertase
(C4b2a3b; C3bBbC3b) that cleaves C5, releasing the
pro-inflammatory fragment C5a and initiating mem-
brane attack complex (MAC) formation. C5 occupies a
central position and, as a consequence, has been identi-
fied as an attractive target for anti-complement drugs.
Indeed, the anti-C5 monoclonal antibody (mAb) eculi-
zumab, a blocker of C5 cleavage by the convertase, is
the most successful anti-complement therapeutic to date
and has transformed the outlook for patients with
paroxysmal nocturnal haemoglobinuria and atypical
haemolytic uraemic syndrome. A recent review listed 34
anti-complement drugs under development; of which
over a third target C5.5
Abbreviations: A, absorbance; BSA, bovine serum albumin; C5, complement component 5; C5D, C5-depleted serum; CFD, com-
plement fixation diluent; ELISA, enzyme-linked immunosorbent assay; mAb, monoclonal antibody; MAC, membrane attack
complex; NHS, normal human serum; NMS, normal mouse serum; NRS, normal rat serum; NRbS, normal rabbit serum; PBS,
phosphate-buffered saline; SDS–PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis
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Characterization of current and new C5-targeted drugs
requires quality reagents, including C5-depleted serum
and pure C5; purification of C5 was described over
50 years ago, requiring multiple precipitation and chro-
matography steps, taking many days and generating poorly
active protein in low yield.6 Later reports described more
efficient methods, focused on reduction of time for purifi-
cation; however, all involved precipitation and/or exposure
to pH shifts, resulting in loss of C5 activity.7–9 A particular
problem was the propensity of C5 to bind C6 when dena-
tured by precipitation or pH shift during the early stages
of purification, resulting in low yields of active pro-
tein.10,11 Immunoaffinity methods using specific antibod-
ies, commonplace for plasma proteins, are reported for
C5;12 however, elution at extremes of pH significantly
compromises C5 activity, in our hands resulting in > 50%
activity loss despite rapid neutralization on elution.
We present an efficient, single-step method of isolating
fully functional C5 with a purification yield of 98%. A
recently described humanized anti-C5 mAb, RO7112689
(C5i mAb, SKY59), was selected by screening for antibod-
ies showing strong binding to C5 at pH 74 but weak or
negligible binding at pH 6.13 This pH-dependent binding
enables recycling of the antibody in vivo through dissocia-
tion from antigen at acidic pH in the endosome (~ pH
55). The antibody was also modified in the Fc region to
eliminate the C1q-binding site and hence its capacity to
activate complement.13 C5 was completely depleted from
serum with a single pass over Sepharose-immobilized
RO7112689 and efficiently eluted from the column at pH
55 with a yield of 98%. RO7112689 cross-reacted with
mouse C5 and efficiently purified C5 from mouse serum.
As the capture mAb in enzyme-linked immunosorbent
assay (ELISA), RO7112689 allowed sensitive and specific
quantification of human and mouse C5 in plasma.
RO7112689, like eculizumab, is reported to block C5
cleavage to prevent C5a and MAC generation;13,14 we
here show that RO7112689 also binds C5 in C5b6 and
inhibits in a reactive lysis system, providing an additional
mechanism of MAC inhibition that may enhance its ther-
apeutic capacity, particularly in sites where C5 may be
atypically activated such as the rheumatoid joint.
Materials and methods
Generation of RO7112689 affinity column
To generate an RO7112689 anti-C5 affinity columns,
RO7112689 antibody (50 mg; Roche, Basel, Switzerland)
was diluted to 5 ml in coupling buffer (02 M Na2HCO3,
05 M NaCl pH 83), immediately injected into a pre-acti-
vated 5-ml HiTRAP N-hydroxysuccinimide-activated
high-performance column (GE Healthcare, Little Chal-
font, UK) and incubated for 1 hr at room temperature.
The column was blocked with 05 M ethanolamine pH 83
and washed into running buffer [Complement Fixation
Diluent (CFD); Oxoid, ThermoFisher, Basingstoke, UK]
containing 05 M NaCl; column eluate was retained to
measure unbound antibody [bicinchoninic acid (BCA)
assay, ThermoFisher]; coupling efficiency was > 90%.
Affinity purification of C5
Normal human serum (NHS) was prepared in-house from
healthy donors. Pooled NHS was applied undiluted to the
RO7112689 column at a rate of 1 ml/min and 4-ml frac-
tions were collected for assessment of C5 depletion. The
column was washed with four volumes of running buffer
(CFD containing 05 M NaCl) then eluted using acetate
buffer pH 55 containing 015 M NaCl. Protein-containing
fractions were collected, pooled and dialysed overnight at
4°C into CFD containing 05 M NaCl. Dialysed protein
was divided into aliquot and stored at 80°. Seven sepa-
rate purifications were performed over 14 months on the
column (Table 1). Between uses the column was stored in
phosphate buffered saline (PBS) containing 001% NaN3
at 4°.
Normal mouse serum (NMS) was prepared from male
mouse blood freshly harvested by cardiac puncture, col-
lected into glass tubes, incubated at room temperature for
5 min then on ice for 20 min. Serum was collected, fil-
tered and pooled. Mouse serum (2 ml) was applied to a
1-ml HiTRAP column with 10 mg RO7112689 immobi-
lized, made as above. The column was washed and eluted
as above; eluted protein was dialysed and stored.
Characterization of purified proteins
C5 (human or mouse; 2 lg) was resolved by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis
Table 1. Purifications performed to date for human and mouse C9
on the RO7112689 columns
Purification no. Column
Serum
applied (ml) Month/year
Calculated
yield
Human
1 5 ml 20 04/2017 –
2 5 ml 30 05/2017 96%
3 5 ml 70 05/2017 97%
4 5 ml 180 05/2017 97%
5 5 ml 50 09/2017 98%
6 5 ml 350 11/2017 98%
7 5 ml 332 05/2018 98%
Mouse
1 1 ml 2 ml 02/2018 92%
2 1 ml 2 ml 03/2018 93%
The same 5-ml column was used for all seven human C5 purifica-
tions. Yield was calculated as described in the Materials and methods
for each purification (except for the first purification)
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(SDS–PAGE) under reducing and non-reducing condi-
tions on 75% PAGE gels, alongside commercially sourced
human C5 (Complement Technology Inc, Tyler, TX).
Gels were stained with Coomassie Blue dye (Thermo-
Fisher). For Western blotting, 1 lg of C5 was resolved by
SDS–PAGE under reducing and non-reducing conditions
as above, then electrophoretically transferred onto 045-
lm nitrocellulose membrane (GE Healthcare). After
transfer, non-specific sites on the membrane were blocked
with 3% bovine serum albumin (BSA) in PBS containing
01% Tween-20 (PBS-T). After washing in PBS-T, the
membrane was incubated with the primary antibody;
RO7112689 (at 1 lg/ml in 3% BSA PBS-T) or polyclonal
(goat) anti-human C5 (CompTech, Texas, USA; A220;
2 lg/ml in 3% BSA PBS-T). After washing, bound anti-
bodies were detected by incubation with donkey anti-
human IgG-horseradish peroxidase or rabbit anti-goat
IgG-horseradish peroxidase conjugate (Jackson Immu-
noResearch, W Baltimore Pike, West Grove, USA; 709-
036-149, 305-035-045) at 1 : 5000 in PBS-T. After wash-
ing, the blot was developed with enhanced chemilumines-
cence (GE Healthcare) and visualized by autoradiography.
Haemolytic assays
To determine the residual lytic capacity of C5-depleted
serum from the RO7112689 affinity column, antibody-
sensitized sheep erythrocytes (sheep blood from TCS Bio-
science, Botolph Claydon, UK) were suspended in CFD at
2% and aliquots were placed in a 96-well round-bot-
tomed plate (50 ll/well) followed by 50 ll/well of each
C5-depleted fraction or 10% NHS as positive control.
Plates were incubated at 37° for 30 min, centrifuged and
haemoglobin in the supernatant was measured by absor-
bance (A) at 405 nm. Percentage lysis was calculated
according to: % Lysis = (Asample – Abackground)/
(Amax – Abackground)*100%. To test the function of puri-
fied C5, protein was added back to C5-depleted serum at
various doses up to 75 lg/ml in undiluted C5-depleted
serum, then tested in haemolysis as above. For measure-
ment of mouse serum haemolytic activity, sheep erythro-
cytes were additionally sensitized with mouse anti-rabbit
IgG (Invitrogen, Carlsbad, CA; #3123) to generate effi-
cient activation of mouse complement. Assays were then
performed as for human serum.
The inhibitory activity of RO7112689 in different spe-
cies sera was investigated by haemolysis assay as
described above. A serial dilution series of the antibody
(100–0 lg/ml; 50 ll/well) was prepared in CFD, then
sheep erythrocytes and serum (50 ll/well of each) were
added as above. Serum dilution for each species was
selected in preliminary experiments to give near-com-
plete haemolysis in the assay: NHS, 125%; male NMS,
20% (using the double-sensitized cells as above); normal
rat serum (NRS), 125%; normal rabbit serum (NRbS),
25%. The volumes of reagents, incubation times and
assay conditions were as described above.
To test C5b6-mediated reactive lysis, guinea-pig erythro-
cytes at 2% in CFD (50 ll/well) were incubated (15 min,
37°) with 50 ll/well C5b6 (in-house, 0125 lg/ml in CFD)
in a 96-well round-bottom plate. C7 (in-house, 07 lg/well)
was added and incubated for 15 min at 37°, then C8 and
C9 (in-house,1 lg/well of each) were added and incubated
for 30 min at 37°. Supernatant was harvested and % Lysis
was calculated as above. In some experiments, RO7112689
at various doses was pre-incubated with C5b6 before expo-
sure to guinea-pig erythrocytes; in other experiments,
RO7112689 at various doses was incubated with C5b6-pre-
coated guinea-pig erythrocytes before the addition of C7.
Complement proteins C5, C6, C7, C8 and C9 were prepared
in-house by affinity purification from serum using specific
monoclonal antibodies immobilized on Sepharose; C5b6
was prepared by incubating C5 and C6 with a fluid-phase
convertase comprising cobra venom factor and activated
factor B.
ELISA for mouse and human C5
To develop an ELISA using RO7112689 as capture, Max-
isorp plates (Nunc, Loughborough, UK) were coated with
RO7112689 (1 lg/ml in bicarbonate buffer, pH 96) at 4°
overnight; wells were blocked (1 hr at 37° with 2% BSA
in PBS), washed in PBS-T. Standard curves of purified
proteins (human C5, C5b6 and C6, and mouse C5; stock
concentrations established using the BCA assay), and
mouse or human serum samples diluted in 02% BSA
PBS, were added in duplicate and incubated for 1 hr at
37°. Wells were washed with PBS-T then incubated (1 hr,
37°) with polyclonal (goat) anti-human C5 cross-reactive
with mouse C5 (CompTech; 2 lg/ml in PBS-T). After
washing, wells were incubated with secondary antibody
(rabbit anti-goat-horseradish peroxidase; Jackson Immu-
noResearch) for 1 hr at 37°. After washing, plates were
developed using o-phenylenediamine dihydrochloride
(SIGMAFASTTM; Sigma-Aldrich, St Louis, MO) and
absorbance (492 nm) was measured. Protein concentra-
tions (lg/ml) in serum samples were automatically calcu-
lated by reference to the standard curve using GRAPHPAD
PRISM (GraphPad, La Jolla, CA, USA). Assay detection
limits, working ranges and assay performance were deter-
mined as described.15
Results
C5 is purified to homogeneity in a single step on the
RO7112689 column
RO7112689-purified C5 demonstrated similar banding
under reducing and non-reducing conditions when com-
pared with commercially available C5 (CompTech), a
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single band in non-reduced SDS–PAGE of 190 000 MW
and two bands under reducing conditions; 115 000 MW
(C5a chain) and 75 000 MW (C5b chain) (Fig. 1a,b).
No other bands were detected in the C5 preparation,
confirming the high purity of the protein. Western blot-
ting using RO7112689 confirmed that RO7112689 bound
the C5b chain as reported previously13 (Fig. 1c). The
average yield from seven separate purifications across
14 months on the same column (Table 1), based upon
ELISA measurement of C5 concentration in pooled NHS
(see below; 813 lg/ml), and concentration of final C5
pool (by BCA) was ~ 98% (e.g. for purification
6 : 350 ml serum, calculated available 2845 mg; purified
277 mg).
Haemolytic assays demonstrated that lytic activity
was completely removed from 350 ml of pooled NHS
in a single pass over the column (Fig. 2a). Adding
C5 to C5-depleted serum (C5D) at physiological
levels fully restored serum lytic activity, confirming
that the C5 depletion was specific (Fig. 2b). C5D
reconstituted with RO7112689-purified C5 had a cal-
culated the 50% haemolytic complement (CH50) of
634 Units, whereas C5D reconstituted with commer-
cial C5 had a CH50 of 402 Units. Titration of C5
into a constant dilution of C5D confirmed that com-
mercially sourced C5 was significantly less efficient at
restoring haemolytic activity; the dose of C5 restoring
to 50% haemolysis in 10% C5D was 2215 ng/ml for
RO7112689-purified C5 and 7147 ng/ml for commer-
cial C5 (Fig. 2c). As little as 2 ng/ml RO7112689-pur-
ified C5 conferred detectable haemolytic activity to
10% C5D (Fig. 2d).
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Figure 1. Characterization of purified C5. (a) SDS–PAGE of purified human C5 (2 lg) from purification #6 (Table 1) compared with commer-
cial C5 (CompTech) on a 75% acrylamide gel; non-reduced (NR), reduced with 5% b-mercaptoethanol (R), proteins were stained with Coomas-
sie Blue. NR; 190 000 MW (intact C5), R; 115 000 MW (C5a chain) and 75 000 MW (C5b chain). RO; RO7112689. (b) Human C5 (2 lg) from
purifications #6 and #7 performed 6 months apart (Table 1) run as above to demonstrate the stability and reproducibility of the procedure. (c)
Western blot of human C5. C5 (1 lg) was resolved on 75% PAGE under NR and R conditions and processed for Western blotting with
RO7112689 or goat anti-human C5 (CompTech). C5; NR; 190 000 MW (intact C5), R; 75 000 MW (C5b chain). Goat anti-human C5 detected
the native C5 in NR conditions and both C5a (115 000 MW) and C5b chains in R conditions, whereas RO7112689 detected C5 in NR condi-
tions and only the C5b chain in R conditions.
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RO7112689 inhibits haemolysis in classical pathway
and reactive lysis systems
Lytic inhibitory properties of RO7112689 were investi-
gated using sheep erythrocytes and NHS at a dose
selected to cause near-100% target lysis. The dose of
RO7112689 was titrated in the assay; the mAb efficiently
inhibited lysis by NHS (Fig. 3a). At the selected dilution
(1 : 80; 50 ll), each well contained ~ 50 ng C5 and near-
complete inhibition was obtained with ~ 25 ng mAb in
the assay. In the reactive lysis system, pre-incubation of
C5b6 with RO7112689 efficiently blocked lysis on subse-
quent addition of C7-C9 (complete inhibition at a molar
ratio C5b6: RO7112689 of 1 : 2; Fig. 3e). In contrast,
incubation of guinea-pig erythrocytes pre-coated with
C5b6 with RO7112689 caused no inhibition of lysis on
the addition of C7-C9, even at the highest antibody doses
(Fig. 3f).
RO7112689 inhibits mouse C5 and efficiently purifies
C5 from mouse serum
Inhibition of haemolytic activity in NMS (male), NRS
and NRbS by RO7112689 was tested as above. The mAb
efficiently inhibited haemolysis by NMS; at the selected
dilution (1 : 5; 50 ll), each well contained ~ 1000 ng C5
and near-complete inhibition was obtained with ~ 500 ng
mAb in the assay (Fig. 3b). Weak inhibition of NRbS and
no inhibition of NRS was seen (Fig. 3c,d).
Passage of mouse serum over the RO7112689 column
efficiently depleted C5 from the serum; elution of the col-
umn using conditions as described above for human-pro-
duced pure mouse C5 in a single step (Fig. 4a). Western
blotting of the purified mouse C5 confirmed RO7112689
binding to the b-chain of mouse C5 (Fig. 4b).
ELISA using RO7112689 enables quantification of C5
in NHS and NMS
Using RO7112689 as capture antibody and a mouse
C5-cross-reactive polyclonal goat anti-human C5 (Comp-
Tech) as detector generated a highly sensitive ELISA cap-
able of measuring human and mouse C5 (Fig. 5a,b). The
assay had a working range of 02–125 ng/ml and a detec-
tion limit of 024 ng/ml. The assay did not detect C3,
C3a or C5a, tested using purified proteins (negative data
not shown). NHS samples from 25 healthy donors and
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Figure 2. Haemolysis assays. (a) Haemolysis assay on run-through fractions (each 4 ml) collected from pooled normal human serum (NHS)
passed over the RO7112689 column; less than 10% lysis seen on each fraction; complete depletion of human C5. NHS (1 : 10) was used as the
positive control (100% lysis). (b) Repletion with C5; C5 sourced either from RO7112689 purification or a commercial source was added back to
neat C5-depleted serum (C5D) at 75 lg/ml; both C5 sources fully restored haemolytic activity but commercial C5 restored serum was less lytic;
calculated CH50 values were: RO7112689 C5, 634 Units; commercial C5, 402 Units. (c) SKY59-purified C5 or commercial C5 were titrated back
into 10% C5D to measure the dose that restored haemolysis to 50%. The 50% lytic dose of RO7112689-purified C5 was 2215 ng/ml, whereas
that for commercial C5 was 7147 ng/ml. (d) Titration to identify the lowest lytic dose of SKY59 purified C5 when added back to C5D; C5 at
2 ng/ml conferred measurable lytic capacity in 10% C5D. RO; RO7112689.
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NMS samples from 11 C57BL/6 mice were measured. C5
in NHS was 796 lg/ml (range; 560–1307), and in male
NMS was 1027 lg/ml (range; 927–1306) (Fig. 5c). The
assay detected C5b6 but not C6 (Fig. 5d); the signal for
C5b6 was lower by ~ 50% compared with the same molar
dose of C5, suggesting some hindrance of binding of the
antibodies to C5b in the C5b6 complex. Binding of C5b6
in the ELISA supports the data, demonstrating capacity
of RO7112689 to inhibit reactive lysis when pre-incubated
with C5b6.
Discussion
The explosion of interest in complement component C5
as a target for therapeutic intervention in complement-
mediated diseases has revealed a need to better
characterize C5 activity and its interactions with current
and future therapeutic agents.5 Such studies require pure,
functionally intact C5 and C5-depleted sera and would
also be facilitated by the availability of rodent C5 protein
and reagents. Purification of C5 has been challenging;
early methods were laborious and inefficient with a very
low recovery of active C5.6–9 Current affinity purification
methods are faster but are complicated by low yield
(> 50%) and poor functional activity of the protein, a
consequence of its pH lability and tendency to associate
with C6 if denatured.10–12 Here we took advantage of a
recently described anti-C5 therapeutic mAb, RO7112689,
that was selected to recycle in vivo by shedding its cargo
when exposed to acidic pH (~ pH55) in the endosome.13
Such antibodies have been engineered to reduce therapeu-
tic dose;16,17 pH-dependence to release soluble antigen in
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Figure 3. Cross-species activity of RO7112689. RO7112689 inhibitory activity was tested in different species sera; human (a), mouse (male) (b),
rat (c) and rabbit (d); serum doses were selected to give near-maximum lysis in the absence of inhibitor (2, 20 125 and 25% respectively for
these four species). RO7112689 was titrated from 100–0 lg/mL; strong inhibition of lysis was observed with human and mouse serum, weak
inhibition with rabbit and no inhibition with rat. NHS, normal human serum; NMS, normal mouse serum; NRS, normal rat serum; NRbS,
normal rabbit serum. Reactive lysis assays used guinea-pig erythrocytes (GpE) and purified complement proteins; C5b6, C7, C8 and C9.
(e) RO7112689 when added to GpE before C5b6 addition efficiently inhibited reactive lysis. (f) RO7112689 added after GpE were pre-coated with
C5b6 complex caused no inhibition of reactive lysis. RO7112689 addition, + RO; no antibody added,  RO.
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the endosome is an essential property.18 Importantly, the
mAb had also been engineered in the Fc region to ablate
C1q binding and hence complement-activating capac-
ity.13,19 RO7112689 immobilized on an affinity column
completely depleted C5 from a large pool of serum and
the bound protein was eluted at pH 55 intact, pure, fully
functional and at 98% yield. The successful isolation of a
labile protein by using a pH-switch mAb to avoid expo-
sure of the protein to extremes of pH during affinity
purification makes the case for similar strategies, using
similar pH-switch-selected antibodies, for purification of
other pH-sensitive proteins. In the original description of
RO7112689, it was stated that the mAb poorly cross-
reacted with mouse C5; however, no data were
included.13 We have not formally measured the affinity of
RO7112689 for mouse C5 but show clearly that it binds
the mouse C5b chain and binds sufficiently strongly to
block C5 activity in mouse serum and to enable single-
step purification of mouse C5 from serum. The cross-
reactivity also enabled the development of a capture
ELISA that allowed quantification of C5 in mouse serum
(mean of 1027 lg/ml from 11 male mice), a useful tool
for future studies.
The mechanism of action of RO7112689 was stated to be
blockade of C5 cleavage by the C5 convertase; this mecha-
nism is the same as that described for the first anti-C5 ther-
apeutic, eculizumab, despite the fact that these mAb bind
different chains of C5.13,14,20 We found that RO7112689
also inhibited in a reactive lysis system using purified C5b6;
when added to C5b6 before incubation with the target gui-
nea-pig erythrocytes, RO7112689 efficiently inhibited reac-
tive lysis, suggesting that the mAb binds C5b6 and prevents
its association with the membrane. This interpretation was
supported by the finding that the mAb did not inhibit
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Figure 4. Purification of mouse C5 on RO7112689. (a) SDS–PAGE of purified mouse C5 (2 lg) on a 4–20% acrylamide gel; non-reduced (NR),
or reduced with 5% b-mercaptoethanol (R), proteins were stained with Coomassie Blue. NR; 190 000 MW (intact C5), R; 115 000 MW (C5a
chain) and 75 000 MW (C5b chain). (b) Western blot of mouse C5. C5 (1 lg) was resolved on 75% PAGE under NR and R conditions and
processed for Western blotting with RO7112689. C5: NR; 190 000 MW (intact C5); R, 75 000 MW (C5b chain).
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Figure 5. ELISA for human and mouse C5. A
C5 sandwich ELISA was generated using
RO7112689 as capture antibody and polyclonal
anti-human C5 as detection. Standard curves
were generated using either human C5 (a) or
mouse C5 (b). Normal human serum (NHS)
samples from 25 healthy donors and normal
mouse serum (NMS) samples from 11 male
C57BL/6 mice were measured (c). The average
level of C5 in NHS was 796 lg/ml (range;
560–1307), and in NMS was 1027 lg/ml
(range; 927–1306). The assay detected human
C5 and C5b6, but not C6; signal intensities of
C5b6 were ~ 50% less intense compared with
the same amount of C5 (d).
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reactive lysis when added after binding of C5b6 to the tar-
get guinea-pig erythrocytes, and by the demonstration that
RO7112689 bound C5b6 in an ELISA. The capacity to inhi-
bit C5b6-mediated lysis might be an important second
mode of action for this mAb, particularly given the growing
list of situations where C5 is atypically activated by pro-
teases to generate a C5b-like fragment capable of triggering
MAC assembly.21–23 Blockers of convertase-mediated C5
cleavage may fail to block these pathologically important
cleavages while C5b6 blockers may still inhibit MAC
formation.
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